Drug
Peanut oral immunotherapy
Peanut oral immunotherapy is a pharmaceutical drug with 6 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
6
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 5 completed trials
Completion Rate
100%(5/5)
Active Trials
1(17%)
Results Posted
40%(2 trials)
Phase Distribution
Ph not_applicable
1
17%
Ph phase_1
2
33%
Ph phase_2
2
33%
Phase Distribution
2
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 2Efficacy & side effects
2(40.0%)
N/ANon-phased studies
1(20.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
5 of 5 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
6
all time
Status Distribution
Active(1)
Completed(5)
Detailed Status
Completed5
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
6
Active
1
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 12 (40.0%)
Phase 22 (40.0%)
N/A1 (20.0%)
Trials by Status
active_not_recruiting117%
completed583%
Recent Activity
1 active trials
Showing 5 of 6
active_not_recruiting
Food Oral Immunotherapy for Peanut Allergy
NCT04222491
completedphase_2
Adjuvant Treatment With Abatacept to Promote Remission During Peanut Oral Immunotherapy
NCT04872218
completednot_applicable
The Grown Up Peanut Immunotherapy Study
NCT03648320
completedphase_2
Determining the Efficacy and Value of Immunotherapy on the Likelihood of Peanut Tolerance: The DEVIL Study
NCT00932828
completedphase_1
Peanut Oral Immunotherapy and Anti-Immunoglobulin E (IgE) for Peanut Allergy
NCT00932282
Clinical Trials (6)
Showing 6 of 6 trials
NCT04222491
Food Oral Immunotherapy for Peanut Allergy
NCT04872218Phase 2
Adjuvant Treatment With Abatacept to Promote Remission During Peanut Oral Immunotherapy
NCT03648320Not Applicable
The Grown Up Peanut Immunotherapy Study
NCT00932828Phase 2
Determining the Efficacy and Value of Immunotherapy on the Likelihood of Peanut Tolerance: The DEVIL Study
NCT00932282Phase 1
Peanut Oral Immunotherapy and Anti-Immunoglobulin E (IgE) for Peanut Allergy
NCT01259804Phase 1
Study of Tolerance to Oral Peanut
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6